Literature DB >> 34274348

Interactions between the microbiota and enteric nervous system during gut-brain disorders.

Steven Fried1, Eve Wemelle1, Patrice D Cani2, Claude Knauf3.   

Abstract

For the last 20 years, researchers have focused their intention on the impact of gut microbiota in healthy and pathological conditions. This year (2021), more than 25,000 articles can be retrieved from PubMed with the keywords "gut microbiota and physiology", showing the constant progress and impact of gut microbes in scientific life. As a result, numerous therapeutic perspectives have been proposed to modulate the gut microbiota composition and/or bioactive factors released from microbes to restore our body functions. Currently, the gut is considered a primary site for the development of pathologies that modify brain functions such as neurodegenerative (Parkinson's, Alzheimer's, etc.) and metabolic (type 2 diabetes, obesity, etc.) disorders. Deciphering the mode of interaction between microbiota and the brain is a real original option to prevent (and maybe treat in the future) the establishment of gut-brain pathologies. The objective of this review is to describe recent scientific elements that explore the communication between gut microbiota and the brain by focusing our interest on the enteric nervous system (ENS) as an intermediate partner. The ENS, which is known as the "second brain", could be under the direct or indirect influence of the gut microbiota and its released factors (short-chain fatty acids, neurotransmitters, gaseous factors, etc.). Thus, in addition to their actions on tissue (adipose tissue, liver, brain, etc.), microbes can have an impact on local ENS activity. This potential modification of ENS function has global repercussions in the whole body via the gut-brain axis and represents a new therapeutic strategy. This article is part of the special Issue on 'Cross Talk between Periphery and the Brain'.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Enteric nervous system; Enterosynes; Gut microbiota; Gut-brain axis; Neurodegenerative disorders

Mesh:

Year:  2021        PMID: 34274348     DOI: 10.1016/j.neuropharm.2021.108721

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

1.  Glucose Stimulates Gut Motility in Fasted and Fed Conditions: Potential Involvement of a Nitric Oxide Pathway.

Authors:  Eve Wemelle; Lionel Carneiro; Anne Abot; Jean Lesage; Patrice D Cani; Claude Knauf
Journal:  Nutrients       Date:  2022-05-23       Impact factor: 6.706

Review 2.  Tapping into 5-HT3 Receptors to Modify Metabolic and Immune Responses.

Authors:  Helen Irving; Ilona Turek; Christine Kettle; Nor Yaakob
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 5.923

Review 3.  Gastrointestinal Microbiome and Neurologic Injury.

Authors:  Eric J Panther; William Dodd; Alec Clark; Brandon Lucke-Wold
Journal:  Biomedicines       Date:  2022-02-21

Review 4.  Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia.

Authors:  Nayla Munawar; Aftab Ahmad; Munir Ahmad Anwar; Khalid Muhammad
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

5.  Association of gut microbiota with sort-chain fatty acids and inflammatory cytokines in diabetic patients with cognitive impairment: A cross-sectional, non-controlled study.

Authors:  Yage Du; Xiaoying Li; Yu An; Ying Song; Yanhui Lu
Journal:  Front Nutr       Date:  2022-07-22

6.  Microbiota-derived metabolites as drivers of gut-brain communication.

Authors:  Hany Ahmed; Quentin Leyrolle; Ville Koistinen; Olli Kärkkäinen; Sophie Layé; Nathalie Delzenne; Kati Hanhineva
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 7.  Neurohormonal Changes in the Gut-Brain Axis and Underlying Neuroendocrine Mechanisms following Bariatric Surgery.

Authors:  Eirini Martinou; Irena Stefanova; Evangelia Iosif; Angeliki M Angelidi
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.